|
Jun 10
|
Better Biotech Stock: Viking Therapeutics vs. Madrigal Pharmaceuticals
|
|
Jun 6
|
Madrigal Pharmaceuticals Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra™ (resmetirom) Presented at the EASL Congress
|
|
May 8
|
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q1 2024 Earnings Call Transcript
|
|
May 8
|
Madrigal Pharmaceuticals Inc (MDGL) (Q1 2024) Earnings Call Transcript Highlights: Navigating ...
|
|
May 7
|
Madrigal Pharmaceuticals Reports Mixed Q1 2024 Results Amidst Rezdiffra Launch
|
|
May 7
|
Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates
|
|
Apr 24
|
Madrigal Statement on the Passing of Dr. Stephen Harrison
|
|
Apr 23
|
Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024
|
|
Apr 15
|
Latest Insider Selling in April 2024: 10 Stocks to Watch
|
|
Apr 9
|
Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis
|
|
Apr 5
|
Better Booming Biotech Stock: Madrigal Pharmaceuticals vs. Viking Therapeutics
|
|
Apr 4
|
Madrigal Pharmaceuticals Inc Director James Daly Sells 32,489 Shares
|
|
Apr 4
|
Madrigal Pharmaceuticals Inc Director Richard Levy Sells 11,000 Shares
|
|
Apr 4
|
Madrigal Pharmaceuticals Inc Director Kenneth Bate Sells 32,489 Shares
|
|
Apr 3
|
1 No-Brainer Growth Stock to Buy Now
|
|
Apr 2
|
The 3 Best Biotech Stocks to Buy in April 2024
|
|
Mar 29
|
Better Buy: Viking Therapeutics vs. Madrigal Pharmaceuticals
|
|
Mar 29
|
Is This Healthcare Stock a Screaming Buy After Scoring a Huge Drug Approval?
|
|
Mar 26
|
Here's 1 Huge New Reason to Buy Madrigal Pharmaceuticals Stock
|
|
Mar 22
|
This Under-the-Radar Stock Just Hit a Major Milestone: Time to Buy?
|